IDC001 | 항체신약

IDC001 | 항체신약

Bispecific Antibody
anti-PAUF, anti-CTHRC1
PAUF와 CTHRC1이 높게 발현되는 암을 치료하기 위한 이중 특이적 항체

요약 | 췌장암, 난소암 항체신약 IDC001

IDC001은 PBP1510과 PBP1710이 결합된 이중 특이적 항체로, PAUF와 CTHRC1이 높게 발현되고 일차 치료제에 내성이 생긴 췌장암, 간암, 난소암 등을 치료하기 위해 디자인된 항체입니다.

간행물

[1] CTHRC1 may serve as a prognostic biomarker for hepatocellular carcinoma. Onco Targets Ther (2019).

[2] Elevated expression of PAUF is associated with poor prognosis and chemoresistance in epithelial ovarian cancer. Sci Rep (2018).

[3] Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis. PLOS ONE (2013).

[4] Efficient targeting and tumor retardation effect of PAUF-specific RNA replacement in pancreatic cancer mouse model. Cancer Lett (2014).

[5] PAUF, a novel up-regulated secretory protein in pancreatic ductal adenocarcinoma. Cancer Sci (2009).

임상 연구 단계

Pipeline : IDC 001

Category :
bs-Ab (bispecific antibody)

Indication :
췌장암 Pancreatic Cancer, 
난소암 Ovarian Cancer

Development Stage

  • Cloning 20% 20%